Raymond James initiated coverage on Erasca with a new price target
$ERAS
Biotechnology: Pharmaceutical Preparations
Health Care
Raymond James initiated coverage of Erasca with a rating of Outperform and set a new price target of $5.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/26/2025 | $5.00 | Outperform | Raymond James |
| 11/18/2024 | $6.00 | Buy | Jefferies |
| 3/11/2024 | $8.00 | Overweight | CapitalOne |
| 1/5/2024 | $11.00 → $6.00 | Buy → Neutral | BofA Securities |
| 10/11/2023 | $10.00 | Buy | H.C. Wainwright |
| 3/30/2023 | $9.00 | Buy | Mizuho |
| 2/24/2023 | $10.00 | Buy | Goldman |
| 2/3/2023 | $15.00 | Equal-Weight → Overweight | Morgan Stanley |
4 - Erasca, Inc. (0001761918) (Issuer)
4 - Erasca, Inc. (0001761918) (Issuer)
4 - Erasca, Inc. (0001761918) (Issuer)